BIA 102474

Drug Profile

BIA 102474

Alternative Names: BIA 10; BIA 10 2474

Latest Information Update: 15 Mar 2016

Price : $50

At a glance

  • Originator BIAL
  • Class Neuropsychotherapeutics
  • Mechanism of Action Fatty acid amide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Neurological disorders; Pain; Psychiatric disorders

Most Recent Events

  • 11 Mar 2016 Suspended - Phase-I for Psychiatric disorders in Portugal (PO) before March 2016 (Bial pipeline; March 2016)
  • 11 Mar 2016 Suspended - Phase-I for Neurological disorders in Portugal (PO) before March 2016 (Bial pipeline; March 2016)
  • 11 Mar 2016 Phase-I clinical trials in Psychiatric disorders in Portugal (PO) before March 2016 (Bial pipeline; March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top